The Long and Short
Commodity price collapse points to Unigel restructuring
This document is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt research reports prepared for retail investors. This material does not constitute research.
Unigel’s recent decision to engage Moelis & Company as its financial advisor and Felsberg Advogados as legal advisor does not come as a surprise following disappointing first quarter 2023 results and a price collapse in agricultural commodities ammonia and urea. The announcement has shifted the market’s attention towards the potential risks of a recuperação judicial, or judicial recovery for the company, in Brazil, or at the very least, an out-of-course restructuring.
In the first quarter this year, Unigel reported weaker-than-expected performance, reflecting continued deterioration in operations in the second half of 2022. Both end prices and volumes declined compared to the previous year in both chemicals and agro. Consequently, EBITDA plummeted by 82% year-on-year to R$104 million, resulting in net leverage rising from 1.1x in the previous quarter to 2.2x. The company had to address cash burn, while the last-12-month EBITDA calculation declined significantly.
The agro business saw a substantial decline in the prices of its main products during the quarter, with ammonia dropping 33.4% and urea 35.6%. The decline has persisted into the current quarter, with ammonia prices falling from approximately $750 a ton in the first quarter to around $400 per ton. Similarly, urea prices have dropped to approximately $300 a ton from $375 a ton in the first quarter of 2023 and $727 a ton in the first quarter of 2022. These price fluctuations have led to a potential 50% decrease in production for granular urea, a more standardized product, as the operating costs at the Sergipe facility become less viable. The facility has been offline since April. Additionally, the linkages to Brent, a benchmark for the industry, have impacted margins, with the effects of higher raw material costs expected to squeeze spreads throughout 2023.
In chemicals, pricing for main products like acrylonitrile and polystyrene has shown less volatility. However, the domestic market, particularly in the styrenics footprint, has faced significant price pressures despite stable order volumes. Acrylics, which primarily exports to Asia, has experienced challenges in both pricing and demand. Although some signs of recovery have emerged in the current quarter, a substantial uplift is not anticipated until at least the second half of 2023.
While the firsts quarter 2023 may have marked the trough of the chemicals segment, prices have further deteriorated in the agro segment during the second quarter. This suggests a very weak financial report for the second quarter, with negative EBITDA expected for agro. Management acknowledged the challenges of rising net leverage during the earnings call but seemed to understate the anticipated impact on credit metrics given the current market pricing.
It seems evident that Unigel will breach its covenants in the second quarter this year, necessitating a waiver from local debenture holders, which is expected to occur but possibly requiring collateral. This breach will also hinder the company’s ability to incur additional debt, as per the 3.5x incurrence covenant in the 2026 bonds. This restriction is crucial to fund cash burn and the scaled-back capital expenditure program, which initially aimed for approximately $40 million USD of deployment throughout the year. The planned expenditure includes projects such as the sulphuric acid project, the Green Hydrogen project, and maintenance spending. Given the anticipated sustained pressure on EBITDA, it is likely that both expansionary projects will be delayed to preserve capital expenditure. Additional credit line drawdowns may be required for the Sulphuric project.
As of the end of March, Unigel reported approximately R$1 billion in unused credit lines. However, much of this amount is uncommitted and no longer serves as a potential source of liquidity due to current operating conditions. Presently, the company has an estimated R$200 million in potential availability, with R$100 million of that amount with BNB, specifically for the sulphuric plant. In April, the company also structured and drew on a R$150 million ECA with Caixa to bolster liquidity ahead of anticipated cash burn and covenant-related constraints in the third quarter.
Looking ahead, as the market sentiment remains highly negative, ratings downgrades are imminent. However, the current bond prices are not relevant to the trade theses. Unigel has begun exploring asset sales to generate cash, with a Mexican acrylic sheets plant being a likely source of liquidity. Nonetheless, divesting this plant, which generates over $12 million in annual EBITDA, would worsen credit ratios. Considering Unigel is a forced seller, it is unlikely to achieve a multiple of over 8x in the current market.
Typically, at this stage of the liquidity cycle, companies turn to shareholders for potential support. Although Unigel’s founder and owner, Henri Slezynger, has indicated the availability of capital if needed, there have been no substantial discussions regarding equity injections, and thus no positive near-term headlines are anticipated. As a result, while bond prices briefly hit a low of 24 cents on the dollar before settling in the low $30s, the transition of bond holdings from long-only investors to the alternative or distressed investor set is still in its early stages, and further price volatility seems likley. This includes the anticipated release of the very weak second quarter 2023 earnings report and the possibility of ceasing interest payments as the company conserves cash and proceeds with a restructuring.
This material is intended only for institutional investors and does not carry all of the independence and disclosure standards of retail debt research reports. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This message, including any attachments or links contained herein, is subject to important disclaimers, conditions, and disclosures regarding Electronic Communications, which you can find at https://portfolio-strategy.apsec.com/sancap-disclaimers-and-disclosures.
Important Disclaimers
Copyright © 2024 Santander US Capital Markets LLC and its affiliates (“SCM”). All rights reserved. SCM is a member of FINRA and SIPC. This material is intended for limited distribution to institutions only and is not publicly available. Any unauthorized use or disclosure is prohibited.
In making this material available, SCM (i) is not providing any advice to the recipient, including, without limitation, any advice as to investment, legal, accounting, tax and financial matters, (ii) is not acting as an advisor or fiduciary in respect of the recipient, (iii) is not making any predictions or projections and (iv) intends that any recipient to which SCM has provided this material is an “institutional investor” (as defined under applicable law and regulation, including FINRA Rule 4512 and that this material will not be disseminated, in whole or part, to any third party by the recipient.
The author of this material is an economist, desk strategist or trader. In the preparation of this material, the author may have consulted or otherwise discussed the matters referenced herein with one or more of SCM’s trading desks, any of which may have accumulated or otherwise taken a position, long or short, in any of the financial instruments discussed in or related to this material. Further, SCM or any of its affiliates may act as a market maker or principal dealer and may have proprietary interests that differ or conflict with the recipient hereof, in connection with any financial instrument discussed in or related to this material.
This material (i) has been prepared for information purposes only and does not constitute a solicitation or an offer to buy or sell any securities, related investments or other financial instruments, (ii) is neither research, a “research report” as commonly understood under the securities laws and regulations promulgated thereunder nor the product of a research department, (iii) or parts thereof may have been obtained from various sources, the reliability of which has not been verified and cannot be guaranteed by SCM, (iv) should not be reproduced or disclosed to any other person, without SCM’s prior consent and (v) is not intended for distribution in any jurisdiction in which its distribution would be prohibited.
In connection with this material, SCM (i) makes no representation or warranties as to the appropriateness or reliance for use in any transaction or as to the permissibility or legality of any financial instrument in any jurisdiction, (ii) believes the information in this material to be reliable, has not independently verified such information and makes no representation, express or implied, with regard to the accuracy or completeness of such information, (iii) accepts no responsibility or liability as to any reliance placed, or investment decision made, on the basis of such information by the recipient and (iv) does not undertake, and disclaims any duty to undertake, to update or to revise the information contained in this material.
Unless otherwise stated, the views, opinions, forecasts, valuations, or estimates contained in this material are those solely of the author, as of the date of publication of this material, and are subject to change without notice. The recipient of this material should make an independent evaluation of this information and make such other investigations as the recipient considers necessary (including obtaining independent financial advice), before transacting in any financial market or instrument discussed in or related to this material.
Important disclaimers for clients in the EU and UK
This publication has been prepared by Trading Desk Strategists within the Sales and Trading functions of Santander US Capital Markets LLC (“SanCap”), the US registered broker-dealer of Santander Corporate & Investment Banking. This communication is distributed in the EEA by Banco Santander S.A., a credit institution registered in Spain and authorised and regulated by the Bank of Spain and the CNMV. Any EEA recipient of this communication that would like to affect any transaction in any security or issuer discussed herein should do so with Banco Santander S.A. or any of its affiliates (together “Santander”). This communication has been distributed in the UK by Banco Santander, S.A.’s London branch, authorised by the Bank of Spain and subject to regulatory oversight on certain matters by the Financial Conduct Authority (FCA) and the Prudential Regulation Authority (PRA).
The publication is intended for exclusive use for Professional Clients and Eligible Counterparties as defined by MiFID II and is not intended for use by retail customers or for any persons or entities in any jurisdictions or country where such distribution or use would be contrary to local law or regulation.
This material is not a product of Santander´s Research Team and does not constitute independent investment research. This is a marketing communication and may contain ¨investment recommendations¨ as defined by the Market Abuse Regulation 596/2014 ("MAR"). This publication has not been prepared in accordance with legal requirements designed to promote the independence of research and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The author, date and time of the production of this publication are as indicated herein.
This publication does not constitute investment advice and may not be relied upon to form an investment decision, nor should it be construed as any offer to sell or issue or invitation to purchase, acquire or subscribe for any instruments referred herein. The publication has been prepared in good faith and based on information Santander considers reliable as of the date of publication, but Santander does not guarantee or represent, express or implied, that such information is accurate or complete. All estimates, forecasts and opinions are current as at the date of this publication and are subject to change without notice. Unless otherwise indicated, Santander does not intend to update this publication. The views and commentary in this publication may not be objective or independent of the interests of the Trading and Sales functions of Santander, who may be active participants in the markets, investments or strategies referred to herein and/or may receive compensation from investment banking and non-investment banking services from entities mentioned herein. Santander may trade as principal, make a market or hold positions in instruments (or related derivatives) and/or hold financial interest in entities discussed herein. Santander may provide market commentary or trading strategies to other clients or engage in transactions which may differ from views expressed herein. Santander may have acted upon the contents of this publication prior to you having received it.
This publication is intended for the exclusive use of the recipient and must not be reproduced, redistributed or transmitted, in whole or in part, without Santander’s consent. The recipient agrees to keep confidential at all times information contained herein.